Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences
November 12 2024 - 7:05AM
Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology
company pursuing development of targeted therapies for oncology,
today announced that Brian Sullivan, Chief Executive Officer, and
Co-founder of Celcuity, will present and be available for
one-on-one investor meetings at the following investor conferences:
- A fireside chat at the Stifel 2024 Healthcare Conference at
1:15 p.m. ET on Tuesday, November 19, 2024. A live webcast will be
available using this weblink:
https://wsw.com/webcast/stifel96/celc/2061562; and
- A fireside chat at the Jefferies London Healthcare Conference
at 11:30 a.m. GMT/6:30 a.m. ET on Thursday, November 21, 2024. A
live webcast will be available using this weblink:
https://wsw.com/webcast/jeff315/celc/1814988
About Celcuity
Celcuity is a clinical-stage biotechnology company focused on
development of targeted therapies for treatment of multiple solid
tumor indications. The company's lead therapeutic candidate is
gedatolisib, a potent, pan-PI3K and mTOR inhibitor. Its mechanism
of action and pharmacokinetic properties are highly differentiated
from other currently approved and investigational therapies that
target PI3K or mTOR alone or together. A Phase 3 clinical trial,
VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant
with or without palbociclib in patients with HR+/HER2- advanced
breast cancer is currently enrolling patients. More detailed
information about the VIKTORIA-1 study can be found
at ClinicalTrials.gov . A Phase 1b/2 clinical trial,
CELC-G-201, evaluating gedatolisib in combination with darolutamide
in patients with metastatic castration resistant prostate cancer,
is enrolling patients. A Phase 3 clinical trial, VIKTORIA-2,
evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as
first-line treatment for patients with HR+/HER2- advanced breast
cancer is expected to begin enrolling patients in the second
quarter of 2025. Celcuity is headquartered in Minneapolis. Further
information about Celcuity can be found
at www.celcuity.com . Follow us
on LinkedIn and Twitter .
Contacts: Celcuity Inc. Brian
Sullivan, bsullivan@celcuity.com Vicky Hahne,
vhahne@celcuity.com (763) 392-0123
ICR Westwicke Maria Yonkoski,
maria.yonkoski@westwicke.com (203) 682-7167
Celcuity (NASDAQ:CELC)
Historical Stock Chart
From Nov 2024 to Dec 2024
Celcuity (NASDAQ:CELC)
Historical Stock Chart
From Dec 2023 to Dec 2024